Clinical trial
PhII ICb With/Without Erbitux in MBC Pts
NCT00248287 · US Oncology Research, Industry · Active, not recruiting
Key facts
| NCT number | NCT00248287 |
|---|---|
| Title | PhII ICb With/Without Erbitux in MBC Pts |
| Official title | Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer |
| Acronym | CA225200 |
| Lead sponsor | US Oncology Research, Industry |
| Collaborators | Bristol-Myers Squibb Industry Pfizer |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux |
| Enrollment | 154 |
| Start date | Jul 28, 2005 |
| Primary completion | Dec 1, 2025 |
| Completion | Dec 1, 2026 |
| First posted | Nov 3, 2005 |
| Last update posted | Jan 29, 2025 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: